UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline
Painful Skin Abscesses, Myasthenia Gravis And Refractory Epilepsy Targeted
Executive Summary
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
You may also be interested in...
UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
Roche Partners With UCB On Anti-Tau Alzheimer’s Drug
UCB gets $120m up front from Roche for option rights to UCB0107 and retains full rights to the drug in progressive supranuclear palsy.
UCB Buoyed By More Positive Bimekizumab Data
The Belgian group has a lot of catching up to do with Cosentyx and Taltz already well established but is confident bimekizumab’s mechanism of action, which neutralizes both IL-17A and IL-17F cytokines, offers an advantage over those two blockbusters.